BioWorld

July 19, 2005

View Archived Issues

Affymax Series D Garners $60M To Boost Hematide

Affymax Inc. raised $60 million in a Series D financing to push along its Phase II candidate Hematide for anemia, which is expected to be studied in four separate trials by late fall. (BioWorld Today) Read More

Lexicon Awarded $35M Grant For Genetic Library In Texas

Read More

XOMA Terminates $73M BPI Deal With Zephyr Sciences

Read More

CombinatoRx Out-Licenses Oncology Drug To HenKan

Read More

Genomic Health Inc.'s IPO: $75M For Diagnostic Tests

Read More

Other News To Note

Read More